



August 2021

### **NCHIV21virtual: abstracts submission guidelines**

The 14th Netherlands Conference on HIV Pathogenesis, Epidemiology, Prevention and Treatment (NCHIV) this year once again will be held virtually and will take place on **Tuesday 23 November 2021 (09:00-17:30 CET / GMT+1)**. It is 40 years since the first cases of AIDS were reported, a milestone the conference will be reflecting on.

The program will include both pre-recorded and “live”, interactive, components. For more information about the program, go to: [nchiv.org](http://nchiv.org)

Researchers are invited to submit original research abstracts across all scientific disciplines relevant to the themes of the conference (HIV pathogenesis, epidemiology, prevention and treatment). Submitted research must be affiliated to a Dutch research institution; researchers themselves may be working either in or outside the Netherlands. Abstracts on SARS-CoV-2/ COVID-19 which are of direct relevance to the field of HIV are also very much welcomed. For a detailed overview of all abstract categories, see below under heading “Abstract categories”.

### **Submission guidelines**

Abstracts can only be submitted online via the official NCHIV21virtual abstract submission portal ([LINK](#)); submissions by post or email will not be considered.

Abstracts must be written in English.

The abstract text body is limited to a maximum of 400 words. Titles are limited to 30 words.

Tables or figures (in JPG, GIF, TIFF or PNG with ideally 600 dpi, a minimum size of 500 KB and a maximum size of 10 MB) may be included, but may not exceed a maximum of two in total. These will not count toward the word limit, nor will any information about authors, institutions and study groups.

Abstracts should be structured and include succinct statements outlining:

- **Background:** study objectives, hypothesis or description of the problem;
- **Methods:** method(s) used or approach taken (incl. statistical analyses when appropriate);
- **Results:** present as clearly and in as much detail as possible the findings/outcome of the study. Please summarize any specific results;

- **Conclusion:** description of the main outcome of the study, and explain the significance of your findings, and future implications of the results.

Authors are strongly encouraged to provide proper quantification of key results, including from experimental basic-/translational research, in the form of an illustrative table or figure.

It is authors' responsibility to submit a correctly-written abstract. Any errors in spelling, grammar or scientific fact will be reproduced as provided by the author.

### **Abstract categories**

The abstract category is the general heading under which your abstract will be reviewed. During the abstract submission process you will be asked to select the abstract category which best suits the subject of your abstract. The NCHIV21 virtual abstract categories are:

- Virology of HIV
- Pathogenesis of HIV including Human Studies and Animal Models
- HIV Reservoirs, Latency, and pre-clinical Curative Strategies
- Host Immune Responses to HIV Infection and Vaccines, and Immunotherapy
- Other HIV basic and translational research
- Antiviral Therapy: Pre-Clinical Data, Randomized Trials, Efficacy and Effectiveness Studies
- Clinical Pharmacology
- HIV Drug Resistance
- Complications of HIV Infection and Antiretroviral Therapy
- HIV and Hepatitis co-infection
- Tuberculosis and Other Opportunistic Infections in HIV
- Maternal and Fetal HIV
- HIV in Infants, Children and Adolescents
- Clinical studies of HIV Cure and Remission
- Other HIV clinical research
- HIV epidemiology
- Phylogenetics/ Molecular Epidemiology of HIV
- Testing
- HIV Prevention Interventions

- Implementation and Models of Treatment, Prevention and Care
- HIV & Contraception, Sexually Transmitted Infections, and Reproductive Health
- Other HIV Epidemiology research
- SARS-CoV-2/COVID-19 pathogenesis, epidemiology, treatment and prevention research in relation to HIV

### **Resubmission policy**

Abstracts which have previously been presented at regional, national or international meetings may be considered for NCHIV recognizing that the audience reach may be greater/different.

Work that has been previously presented at a regional, national or international meetings however may only be submitted provided new findings have been included (e.g. relevant updates or subanalyses which have not been previously presented).

The submitting author will be required to provide details of any previous publication or presentation, along with a justification of why the abstract merits consideration. This information will be considered by the NCHIV Board when selecting abstracts for the NCHIV21 virtual conference program.

### **Rule of two**

During NCHIV21 virtual any individual author may only present a maximum of two abstracts. The number of submissions however is not limited. Should an author have more than two abstracts accepted, a co-author should be asked to present.

### **Deadline for abstract submission**

Abstracts must be submitted by **Friday 24 September 2021 (18:00 CET/ GMT+1)**. Abstracts submitted after this time will not be considered.

### **Submission confirmation**

Shortly after completing the online abstract submission process, the submitting author will receive a confirmation email. If you do not receive an email (do check your spam folder) contact us at [registration@parthen.nl](mailto:registration@parthen.nl) and [organisation@nchiv.org](mailto:organisation@nchiv.org).

### **Abstract review and scoring**

All submitted abstracts go through a blinded peer-review and scoring process carried out by a multidisciplinary group of Netherlands-based research professionals and experts invited by the NCHIV Board. The following criteria will be considered by the reviewers:

- Is there a clear background and justified objective?
- Is the methodology or design appropriate for the objectives?
- Are the results important and clearly presented?
- Are the conclusions supported by the results?
- Is the study original, and does it contribute to the field?

### **Abstract selection**

Based on review scores provided by the reviewers, the NCHIV Board makes a final selection of abstracts for inclusion in the NCHIV21 virtual conference program. Accepted abstracts can be considered for one of the following:

- **Oral presentation:** lasting approx. 10 minutes during a plenary session. Ahead of the conference the presentation will be professionally prerecorded with support of the NCHIV21 virtual tech team. During the conference the prerecorded presentation will be played during a plenary session followed by a “live”, moderated Q&A;
- **Oral spotlight:** lasting approx. 5 minutes (max 2 slides) during a parallel break out session. Ahead of the conference the presentation will be professionally prerecorded with support of the NCHIV21 virtual tech team. During the conference the prerecorded presentation will be played during a parallel break out session followed by a “live”, moderated Q&A.

Contact details (email) of all presenting authors will also be made available on the online conference portal to allow for and promote further interaction between presenters and audience, both during and after the conference.

Conference content will be available to registered delegates-only on the conference platform until December 17, 2021. Starting January conference content will be freely available to the public through the NCHIV website.

### **Notification of acceptance or rejection**

Notification of acceptance or rejection will be sent to the submitting author by **mid-October 2021**. Please note that the author receiving the notification email is responsible for informing all co-authors of the status of the abstract. Authors whose abstracts have been accepted will receive instructions how to prepare for their oral presentation or oral spotlight.

### **Publication policy**

All accepted abstracts and the final program will be published on [nchiv.org](http://nchiv.org). In addition, all NCHIV21 virtual conference attendees will receive a pdf-format conference pack including the program and an overview of all accepted abstracts.

## Conference registration

Presenting authors, like all conference attendees, are required to register for the conference. They need to ensure having done so by **Friday 12 November (18:00 CET/ GMT+1)**. To register, please go to [nchiv.org](http://nchiv.org).

## Joep Lange & Jacqueline van Tongeren Junior Investigator's Award

The NCHIV Board will select the highest scoring abstract submitted by a junior researcher to be awarded the Joep Lange & Jacqueline van Tongeren Junior Investigator's Award.

To be considered for the award, authors must be in the process of gaining or have recently gained their PhD. In addition, the abstract must relate to work carried out during their PhD trajectory.

The winning abstract author will receive a prize to the value of €1000 to be spent on a study or conference of their choice within one year of NCHIV21virtual.

The winning author will be announced during the closing session during of the conference.

## Reminder critical dates

- **Friday 24 September (18:00 CET/ GMT+1):** abstract submission deadline
- **Mid-October:** notification of abstract acceptance or rejection
- **Friday 12 November (18:00 CET/ GMT+1):** conference registration deadline for presenting authors

## Help & contact details

Should you have any questions about or encounter issues throughout the abstract submission process, please contact: [organisation@nchiv.org](mailto:organisation@nchiv.org) and [registration@parthen.nl](mailto:registration@parthen.nl)